TMDX Share Price Performance
US$0
-90.45 (-100.00%)
Price US$0
Fair ValueUS$144.20
Share Pricen/a
TransMedics Group, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 148 Fair Values set on narratives written by author
TMDX Community Narratives
AN
Fair Value
·Fair Value US$144.2 30.1% undervalued intrinsic discount
TMDX: Expanding Organ Donor Pool And Clinical Trials Will Shape Future Direction
2users have liked this narrative
0users have commented on this narrative
61users have followed this narrative
AN
Fair Value
·Fair Value US$190 47.0% undervalued intrinsic discount
Transplant Logistics Will Meet Demand From An Aging World
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$118 14.6% undervalued intrinsic discount
Cost Pressures And Supply Risks Will Weaken Transplant Market Viability
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Cost Pressures And Supply Risks Will Weaken Transplant Market Viability
Key Takeaways Greater emphasis on preventive care and new therapies threaten future demand and technological relevance for the company's solutions. High costs, tightening healthcare budgets, and global risks may put ongoing pressure on margins, growth, and profitability.Read more
AN
US$118
14.6% undervalued intrinsic discount
Fair Value
Revenue
18.45% p.a.
Profit Margin
18.77%
Future PE
27.64x
Price in 2029
US$146.08
Transplant Logistics Will Meet Demand From An Aging World
Key Takeaways Dominance in next-generation organ transplant solutions, logistics, and comprehensive platforms positions TransMedics for rapid global share gains and recurring high-margin revenue growth. Structural healthcare trends and expansion into new geographies create a long runway for multi-organ adoption and sustained long-term revenue momentum.Read more
AN
US$190
47.0% undervalued intrinsic discount
Fair Value
Revenue
20.32% p.a.
Profit Margin
22.92%
Future PE
34.74x
Price in 2029
US$234.85
TMDX: Expanding Organ Donor Pool And Clinical Trials Will Shape Future Direction
Key Takeaways Rising global demand for organ transplants and healthcare modernization support broader adoption and revenue growth for TransMedics' OCS platform. Expansion into new organs, next-gen products, and recurring service offerings increase market potential and support stronger margins.Read more
AN
US$144.2
30.1% undervalued intrinsic discount
Fair Value
Revenue
18.18% p.a.
Profit Margin
17.97%
Future PE
37.75x
Price in 2029
US$180.09
Trending Discussion
Recently Updated Narratives
AN
TMDX: Clinical Trials And 2026 Outlook Will Drive The Next Leg
Fair Value: US$118 14.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TMDX: Organ Platform Expansion And Trials Will Support Future Repricing
Fair Value: US$190 47.0% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TMDX: Competitor Clearance And New Campus Will Shape Balanced Future Prospects
Fair Value: US$144.2 30.1% undervalued intrinsic discount
61 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
TransMedics Group, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 05, 2026
- 5.51
- 59.92%
- 31.43%
- 108.3%
About TMDX
- Founded
- 1998
- Employees
- 898
- CEO
- WebsiteView website
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
